BACKGROUND: Frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) is a pathological entity characterized by motor neuron degeneration and frontotemporal lobar degeneration. The ability to detect the clinical signs of dementia and motor neuron disease in pathologically confirmed FTLD-MND has not been assessed. OBJECTIVES: To determine if all cases of pathologically confirmed FTLD-MND have clinical evidence of frontotemporal dementia and motor neuron disease, and to determine the possible reasons for misdiagnosis. METHOD: Review of historical records and semiquantitative analysis of the motor and extramotor pathological findings of all cases of pathologically confirmed FTLD-MND. RESULTS: From a total of 17 cases of pathologically confirmed FTLD-MND, all had clinical evidence of frontotemporal dementia, while only 10 (59%) had clinical evidence of motor neuron disease. Semiquantitative analysis of motor and extramotor pathological findings revealed a spectrum of pathological changes underlying FTLD-MND. Hippocampal sclerosis, predominantly of the subiculum, was a significantly more frequent occurrence in the cases without clinical evidence of motor neuron disease (P<.01). In addition, neuronal loss, gliosis, and corticospinal tract degeneration were less severe in the other 3 cases without clinical evidence of motor neuron disease. CONCLUSIONS: Clinical diagnostic sensitivity for the elements of FTLD-MND is modest and may be affected by the fact that FTLD-MND represents a spectrum of pathological findings, rather than a single homogeneous entity. Detection of signs of clinical motor neuron disease is also difficult when motor neuron degeneration is mild and in patients with hippocampal sclerosis.
BACKGROUND: Frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) is a pathological entity characterized by motor neuron degeneration and frontotemporal lobar degeneration. The ability to detect the clinical signs of dementia and motor neuron disease in pathologically confirmed FTLD-MND has not been assessed. OBJECTIVES: To determine if all cases of pathologically confirmed FTLD-MND have clinical evidence of frontotemporal dementia and motor neuron disease, and to determine the possible reasons for misdiagnosis. METHOD: Review of historical records and semiquantitative analysis of the motor and extramotor pathological findings of all cases of pathologically confirmed FTLD-MND. RESULTS: From a total of 17 cases of pathologically confirmed FTLD-MND, all had clinical evidence of frontotemporal dementia, while only 10 (59%) had clinical evidence of motor neuron disease. Semiquantitative analysis of motor and extramotor pathological findings revealed a spectrum of pathological changes underlying FTLD-MND. Hippocampal sclerosis, predominantly of the subiculum, was a significantly more frequent occurrence in the cases without clinical evidence of motor neuron disease (P<.01). In addition, neuronal loss, gliosis, and corticospinal tract degeneration were less severe in the other 3 cases without clinical evidence of motor neuron disease. CONCLUSIONS: Clinical diagnostic sensitivity for the elements of FTLD-MND is modest and may be affected by the fact that FTLD-MND represents a spectrum of pathological findings, rather than a single homogeneous entity. Detection of signs of clinical motor neuron disease is also difficult when motor neuron degeneration is mild and in patients with hippocampal sclerosis.
Authors: Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen Journal: Neurobiol Aging Date: 2007-10-18 Impact factor: 4.673
Authors: J L Whitwell; B F Boeve; S D Weigand; M L Senjem; J L Gunter; M C Baker; M DeJesus-Hernandez; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; C R Jack; K A Josephs Journal: Eur J Neurol Date: 2015-02-12 Impact factor: 6.089
Authors: Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Maria Shiung; David S Knopman; Rosa Rademakers; Mike Hutton; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Ronald C Petersen Journal: Arch Neurol Date: 2010-02
Authors: Jennifer L Whitwell; Clifford R Jack; V Shane Pankratz; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Keith A Josephs Journal: Neuroimage Date: 2007-10-10 Impact factor: 6.556
Authors: Jennifer L Whitwell; Clifford R Jack; Matthew L Senjem; Joseph E Parisi; Bradley F Boeve; David S Knopman; Dennis W Dickson; Ronald C Petersen; Keith A Josephs Journal: Neurodegener Dis Date: 2009-03-19 Impact factor: 2.977
Authors: William T Hu; Harro Seelaar; Keith A Josephs; David S Knopman; Bradley F Boeve; Eric J Sorenson; Leo McCluskey; Lauren Elman; Helenius J Schelhaas; Joseph E Parisi; Benno Kuesters; Virginia M-Y Lee; John Q Trojanowski; Ronald C Petersen; John C van Swieten; Murray Grossman Journal: Arch Neurol Date: 2009-11
Authors: Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen Journal: Arch Neurol Date: 2009-02
Authors: Keith A Josephs; Jennifer L Whitwell; Melissa E Murray; Joseph E Parisi; Neill R Graff-Radford; David S Knopman; Bradley F Boeve; Matthew L Senjem; Rosa Rademakers; Clifford R Jack; Ronald C Petersen; Dennis W Dickson Journal: Brain Date: 2013-01-28 Impact factor: 13.501